Co-treatment with Palbociclib and CDK2-specific Inhibitors to Suppress Tumor Adaptation to CDK2 Inhibitors
Characterization of the real-time response of cancer cells to small-molecule CDK2 inhibitors
Published: 16th February 2022

Patents
Seeking
- Licensing